FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1488757278> ?p ?o ?g. }

• W1488757278 abstract "Leiomyosarcoma (LMS) represents 15% of adult sarcomas. Once metastatic, curative options are limited and innovative strategies are needed. TYRO3 and AXL proto-oncogenes belong to TAM family (Tyro3/Axl/Mer) of tyrosine kinase receptors, with oncogenic properties that are often overexpressed or activated in various malignancies. Using kinexus phosphoprotein microarrays (KAM-1.1) and western blot analyses, we evidenced that Tyro3 and Axl are overexpressed in LMS along with Gas6, their ligand. Interestingly LMS samples harbouring high levels of Gas6 and its receptors also presented AKT phosphorylation on S473 residue keeping with previous studies that highlighted AKT- mTOR activation in leiomyosarcomas. Based on these premises, we asked whether Tyro3-Axl axis may drive LMS proliferation and could represent potential targets in these tumors. The overexpression of Tyro3 was found to be associated with a specific miRNA signature, notably with an overexpression of miR22 in LMS tumors. Furthermore Tyro3 and Axl were found overexpressed in a panel of 6 LMS cell lines (SK-LMS-1 from ATCC and IB112, IB118, IB133, IB134 and IB136 from Institut Bergonie), compared with normal human smooth muscle. Tyro3 or Axl knockdown via shRNA retroviral vector reduced cell proliferation by up to 50 and 64% respectively and decreased soft agar colony-forming ability. Crizotinib and foretinib are two tyrosine kinase inhibitors (TKI) targeting Met and Axl. Treatment of LMS cell lines with both TKIs resulted in a significant increase in cell death, with IC 50 values ranging from 3.6 to 14.6µM and 0.7 to 1.8µM, respectively. Annexin V and PI staining revealed that cell death was mainly due to apoptosis. Flow cytometric cell cycle analysis demonstrates that both TKIs altered cell cycle phase distribution. A sub-G1 phase accumulation was observed for one of the cell lines; meanwhile the other cell lines presented a G2 arrest and 4n chromosomes accumulation accompanied by an increase in cell and nucleus sizes. Only foretinib induced nuclear fragmentation consistent with late apoptosis. Pharmacological inhibition also reduced migration and colony formation in soft agar. Drug combinations with an AKT inhibitor led to significant increase in growth inhibition in all tested cell lines. Crizotinib and foretinib reduced activation of Tyro3 or Axl-mediated downstream signaling including MAPK/ERK, PI3K/AKT along with an inhibition of Axl phosphorylation in a dose dependent manner. By immunoprecipitation we observed also a reduction in Tyro3 phosphorylation, following exposure to both agents, showing that Tyro3 is a new target for those drugs. IHC analysis of Tyro3, Axl and Gas6 expression in a cohort of LMS patient is ongoing. In vivo analysis wil be performed. In conclusion these results strongly suggest that Tyro3 and Axl are relevant therapeutic targets for LMS treatment and will be investigated in a proof of concept clinical trial. Citation Format: Carmela Dantas-Barbosa, Francois Le Loarer, Marta Mendiola, Isabelle Treilleux, Frederic Chibon, Hyba El Sayadi, Jean Michel Coindre, Laurent Alberti, Jean-Yves Blay. Tyro3 and Axl receptors tyrosine kinase as potential therapeutic targets in leiomyosarcoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2780. doi:10.1158/1538-7445.AM2014-2780" @default.
• W1488757278 created "2016-06-24" @default.
• W1488757278 creator A5001699241 @default.
• W1488757278 creator A5006945230 @default.
• W1488757278 creator A5022219169 @default.
• W1488757278 creator A5034862693 @default.
• W1488757278 creator A5042202815 @default.
• W1488757278 creator A5047352369 @default.
• W1488757278 creator A5055932045 @default.
• W1488757278 creator A5059400259 @default.
• W1488757278 creator A5079971350 @default.
• W1488757278 date "2014-09-30" @default.
• W1488757278 modified "2023-10-09" @default.
• W1488757278 title "Abstract 2780: Tyro3 and Axl receptors tyrosine kinase as potential therapeutic targets in leiomyosarcoma" @default.
• W1488757278 doi "https://doi.org/10.1158/1538-7445.am2014-2780" @default.
• W1488757278 hasPublicationYear "2014" @default.
• W1488757278 type Work @default.
• W1488757278 sameAs 1488757278 @default.
• W1488757278 citedByCount "0" @default.
• W1488757278 crossrefType "proceedings-article" @default.
• W1488757278 hasAuthorship W1488757278A5001699241 @default.
• W1488757278 hasAuthorship W1488757278A5006945230 @default.
• W1488757278 hasAuthorship W1488757278A5022219169 @default.
• W1488757278 hasAuthorship W1488757278A5034862693 @default.
• W1488757278 hasAuthorship W1488757278A5042202815 @default.
• W1488757278 hasAuthorship W1488757278A5047352369 @default.
• W1488757278 hasAuthorship W1488757278A5055932045 @default.
• W1488757278 hasAuthorship W1488757278A5059400259 @default.
• W1488757278 hasAuthorship W1488757278A5079971350 @default.
• W1488757278 hasConcept C101544691 @default.
• W1488757278 hasConcept C157333092 @default.
• W1488757278 hasConcept C172811965 @default.
• W1488757278 hasConcept C184235292 @default.
• W1488757278 hasConcept C42362537 @default.
• W1488757278 hasConcept C502942594 @default.
• W1488757278 hasConcept C5364575 @default.
• W1488757278 hasConcept C55493867 @default.
• W1488757278 hasConcept C62112901 @default.
• W1488757278 hasConcept C62478195 @default.
• W1488757278 hasConcept C75217442 @default.
• W1488757278 hasConcept C86803240 @default.
• W1488757278 hasConcept C95444343 @default.
• W1488757278 hasConceptScore W1488757278C101544691 @default.
• W1488757278 hasConceptScore W1488757278C157333092 @default.
• W1488757278 hasConceptScore W1488757278C172811965 @default.
• W1488757278 hasConceptScore W1488757278C184235292 @default.
• W1488757278 hasConceptScore W1488757278C42362537 @default.
• W1488757278 hasConceptScore W1488757278C502942594 @default.
• W1488757278 hasConceptScore W1488757278C5364575 @default.
• W1488757278 hasConceptScore W1488757278C55493867 @default.
• W1488757278 hasConceptScore W1488757278C62112901 @default.
• W1488757278 hasConceptScore W1488757278C62478195 @default.
• W1488757278 hasConceptScore W1488757278C75217442 @default.
• W1488757278 hasConceptScore W1488757278C86803240 @default.
• W1488757278 hasConceptScore W1488757278C95444343 @default.
• W1488757278 hasLocation W14887572781 @default.
• W1488757278 hasOpenAccess W1488757278 @default.
• W1488757278 hasPrimaryLocation W14887572781 @default.
• W1488757278 hasRelatedWork W1504455503 @default.
• W1488757278 hasRelatedWork W1519951345 @default.
• W1488757278 hasRelatedWork W1568480125 @default.
• W1488757278 hasRelatedWork W1972674172 @default.
• W1488757278 hasRelatedWork W1979302285 @default.
• W1488757278 hasRelatedWork W2343876970 @default.
• W1488757278 hasRelatedWork W2481883570 @default.
• W1488757278 hasRelatedWork W2501533452 @default.
• W1488757278 hasRelatedWork W2559166357 @default.
• W1488757278 hasRelatedWork W2560491663 @default.
• W1488757278 hasRelatedWork W2577482845 @default.
• W1488757278 hasRelatedWork W2592093063 @default.
• W1488757278 hasRelatedWork W2593083251 @default.
• W1488757278 hasRelatedWork W2886342547 @default.
• W1488757278 hasRelatedWork W2887204203 @default.
• W1488757278 hasRelatedWork W2887326695 @default.
• W1488757278 hasRelatedWork W2914799005 @default.
• W1488757278 hasRelatedWork W2955381543 @default.
• W1488757278 hasRelatedWork W3012487685 @default.
• W1488757278 hasRelatedWork W3082712685 @default.
• W1488757278 isParatext "false" @default.
• W1488757278 isRetracted "false" @default.
• W1488757278 magId "1488757278" @default.
• W1488757278 workType "article" @default.